Curcumin Enhances the Antitumor Effect of ABT-737 Via Activation of the ROS-ASK1-JNK Pathway in Hepatocellular Carcinoma Cells

Overview

Journal Mol Med Rep

Specialty Molecular Biology

Date 2015 Dec 29

PMID 26707143

Citations 13

Authors

Ruinian Zheng

Zhijian You

Jun Jia

Shunhuan Lin

Shuai Han

Aixue Liu

Huidong Long

Senming Wang

Affiliations

Soon will be listed here.

Abstract

At present, the therapeutic treatment strategies for patients with hepatocellular carcinoma (HCC) remain unsatisfactory, and novel methods are urgently required to treat this disease. Members of the B cell lymphoma (Bcl)-2 family are anti‑apoptotic proteins, which are commonly expressed at high levels in certain HCC tissues and positively correlate with the treatment resistance of patients with HCC. ABT-737, an inhibitor of Bcl-2 anti-apoptotic proteins, has been demonstrated to exhibit potent antitumor effects in several types of tumor, including HCC. However, treatment with ABT-737 alone also activates certain pro-survival signaling pathways, which attenuate the antitumor validity of ABT-737. Curcumin, which is obtained from Curcuma longa, is also an antitumor potentiator in multiple types of cancer. In the present study, the synergistic effect of curcumin and ABT-737 on HCC cells was investigated for the first time, to the best of our knowledge. It was found that curcumin markedly enhanced the antitumor effects of ABT-737 on HepG2 cells, which was partially dependent on the induction of apoptosis, according to western blot analysis and flow cytometric apoptosis analysis. In addition, the sustained activation of the ROS-ASK1-c-Jun N-terminal kinase pathway may be an important mediator of the synergistic effect of curcumin and ABT-737. Collectively, these results indicated that the combination of curcumin and ABT-737 can efficaciously induce the death of HCC cells, and may offer a potential treatment strategy for patients with HCC.

Citing Articles

ABT‑737 increases cisplatin sensitivity through the ROS‑ASK1‑JNK MAPK signaling axis in human ovarian cancer cisplatin‑resistant A2780/DDP cells.

Li X, Guo Y, Xing Z, Gong T, Yang L, Yang T Oncol Rep. 2024; 52(3).

PMID: 39054955 PMC: 11292299. DOI: 10.3892/or.2024.8781.

Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers.

Xu J, Dong X, Huang D, Xu P, Zhao Q, Chen B Cancers (Basel). 2023; 15(20).

PMID: 37894324 PMC: 10605442. DOI: 10.3390/cancers15204957.

Cancer Cell Membrane Wrapped Nanoparticles for the Delivery of a Bcl-2 Inhibitor to Triple-Negative Breast Cancer.

Scully M, Wilkins D, Dang M, Hoover E, Aboeleneen S, Day E Mol Pharm. 2023; 20(8):3895-3913.

PMID: 37459272 PMC: 10628893. DOI: 10.1021/acs.molpharmaceut.3c00009.

Curcumin and its Derivatives Targeting Multiple Signaling Pathways to Elicit Anticancer Activity: A Comprehensive Perspective.

Fatima F, Chourasiya N, Mishra M, Kori S, Pathak S, Das R Curr Med Chem. 2023; 31(24):3668-3714.

PMID: 37221681 DOI: 10.2174/0929867330666230522144312.

Induction of Antimicrobial Protein S100A15 Expression by Oral Microbial Pathogens Is Toll-like Receptors-Dependent Activation of c-Jun-N-Terminal Kinase (JNK), p38, and NF-κB Pathways.

Selimovic D, Kharouf N, Carrouel F, Hassan S, Flanagan T, Hassan S Int J Mol Sci. 2023; 24(6).

PMID: 36982421 PMC: 10049289. DOI: 10.3390/ijms24065348.

References

Nasr M, Selima E, Hamed O, Kazem A . Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice. Eur J Pharmacol. 2013; 723:267-75. DOI: 10.1016/j.ejphar.2013.11.022. View

Seki E, Brenner D, Karin M . A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology. 2012; 143(2):307-20. PMC: 3523093. DOI: 10.1053/j.gastro.2012.06.004. View

Effendi K, Sakamoto M . Molecular pathology in early hepatocarcinogenesis. Oncology. 2010; 78(2):157-60. DOI: 10.1159/000312658. View

Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A . Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol. 2012; 56(6):1343-50. PMC: 3355195. DOI: 10.1016/j.jhep.2012.01.009. View

Li Y, Zhang T . Targeting cancer stem cells by curcumin and clinical applications. Cancer Lett. 2014; 346(2):197-205. DOI: 10.1016/j.canlet.2014.01.012. View

Schattenberg J, Schuchmann M, Galle P . Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways. J Gastroenterol Hepatol. 2011; 26 Suppl 1:213-9. DOI: 10.1111/j.1440-1746.2010.06582.x. View

Guo J, Li W, Shi H, Xie X, Li L, Tang H . Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. Mol Cell Biochem. 2013; 382(1-2):103-11. DOI: 10.1007/s11010-013-1723-6. View

Wang G, Zhan Y, Wang H, Li W . ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein. Cancer Chemother Pharmacol. 2011; 69(3):799-805. DOI: 10.1007/s00280-011-1763-0. View

Meiyanto E, Pamungkas Putri D, Asmah Susidarti R, Murwanti R, Sardjiman , Fitriasari A . Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation. Asian Pac J Cancer Prev. 2014; 15(1):179-84. DOI: 10.7314/apjcp.2014.15.1.179. View

10.

Czabotar P, Lessene G, Strasser A, Adams J . Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2013; 15(1):49-63. DOI: 10.1038/nrm3722. View

11.

Prasad S, Gupta S, Tyagi A, Aggarwal B . Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv. 2014; 32(6):1053-64. DOI: 10.1016/j.biotechadv.2014.04.004. View

12.

Yu L, Liu S . Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics. Semin Cancer Biol. 2013; 23(6 Pt B):553-60. DOI: 10.1016/j.semcancer.2013.08.008. View

13.

Ibrahim N, Yu Y, Walsh W, Yang J . Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). Oncol Rep. 2012; 27(5):1303-11. DOI: 10.3892/or.2012.1675. View

14.

Zhang S, Li G, Ma X, Wang Y, Liu G, Feng L . Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1. Cell Signal. 2012; 24(9):1803-9. DOI: 10.1016/j.cellsig.2012.05.009. View

15.

Wang B, Ni Z, Dai X, Qin L, Li X, Xu L . The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells. Mol Cancer. 2014; 13:98. PMC: 4021276. DOI: 10.1186/1476-4598-13-98. View

16.

Sehgal V, Ram P . Network Motifs in JNK Signaling. Genes Cancer. 2013; 4(9-10):409-13. PMC: 3863341. DOI: 10.1177/1947601913507577. View

17.

Geng J, Li X, Lang X, Qiao C, Hu M, Yang J . Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma. Technol Cancer Res Treat. 2013; 13(4):377-85. DOI: 10.7785/tcrt.2012.500389. View

18.

Guo X, Shao X, Liu M, Xu J, Ren L, Zhao J . Effect of bax, bcl-2 and bcl-xL on regulating apoptosis in tissues of normal liver and hepatocellular carcinoma. World J Gastroenterol. 2002; 8(6):1059-62. PMC: 4656380. DOI: 10.3748/wjg.v8.i6.1059. View

19.

Deng Y, Huang H, Lin J . Rotenone induces apoptosis in MCF-7 human breast cancer cell-mediated ROS through JNK and p38 signaling. Mol Carcinog. 2009; 49(2):141-51. DOI: 10.1002/mc.20583. View

20.

Zhou Q, Chen Q, Du J, Wang X, Lu Y, Zhang H . Synergistic effect of combinatorial treatment with curcumin and mitomycin C on the induction of apoptosis of breast cancer cells: a cDNA microarray analysis. Int J Mol Sci. 2014; 15(9):16284-301. PMC: 4200820. DOI: 10.3390/ijms150916284. View